-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Genmab, Raises Price Target to $58

Benzinga·10/07/2026 13:03:32
Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $54 to $58.